Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy

COVID-19 patients at risk of severe disease may be treated with neutralising monoclonal antibodies (mAbs). To minimise virus escape from neutralisation these are administered as combinations e.g. casirivimab+imdevimab or, for antibodies targeting relatively conserved regions, individually e.g. sotro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ragonnet-Cronin, Manon, Nutalai, Rungtiwa, Huo, Jiandong, Dijokaite-Guraliuc, Aiste, Das, Raksha, Tuekprakhon, Aekkachai, Supasa, Piyada, Liu, Chang, Selvaraj, Muneeswaran, Groves, Natalie, Hartman, Hassan, Ellaby, Nicholas, Mark Sutton, J., Bahar, Mohammad W., Zhou, Daming, Fry, Elizabeth, Ren, Jingshan, Brown, Colin, Klenerman, Paul, Dunachie, Susanna J., Mongkolsapaya, Juthathip, Hopkins, Susan, Chand, Meera, Stuart, David I., Screaton, Gavin R., Rokadiya, Sakib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246534/
https://www.ncbi.nlm.nih.gov/pubmed/37286554
http://dx.doi.org/10.1038/s41467-023-37826-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246534/
https://www.ncbi.nlm.nih.gov/pubmed/37286554
http://dx.doi.org/10.1038/s41467-023-37826-w

Ejemplares similares